Eli Lilly and Company recently announced that Jardiance slowed kidney function decline in adults with heart failure with left ventricular ejection fraction (LVEF) over 40 percent regardless of chronic...
Abbott and the American Diabetes Association (ADA) recently launched a joint community health partnership to address diabetes care management among people of color (POC) living with the...
GSK recently announced that its drug, daprodustat, was safe and effective in patients with anemia due to chronic kidney disease (CKD).
The Phase 3 ASCENT trial studied the hypoxia-inducible...
Moderna and Metagenomi recently entered into a strategic research and development collaboration to advance new gene editing systems for in vivo human therapeutic applications.
Under the terms of the...
Gilead and Merck recently announced the start of a Phase 2 clinical study evaluating a combination HIV treatment regimen in adults living with the disease.
The open-label study will evaluate the...
Abbott recently launched a new initiative to increase clinical trial diversity in medical research through training, education, and improved clinical research infrastructure throughout the...
FDA recently approved Novartis’ Scemblix to treat chronic myeloid leukemia (CML) for adult and pediatric patients with Philadelphia chromosome-positive CML in chronic phase.
Scemblix is the...
Novartis and Global Heart Hub recently launched Invisible Nation, a program to bring together a global network of patient organizations and other stakeholders to tackle atherosclerotic cardiovascular...
Roche recently launched the AVENIO Tumor Tissue CGP Kit, a genomic profiling kit to allow laboratories to expand their oncology research in-house.
AVENIO Tumor Tissue CGP Kit is a...
Daiichi Sankyo and AstraZeneca recently entered into a second clinical trial collaboration and supply agreement with Merck to evaluate an antibody-drug conjugate with Keytruda in patients with...
Eli Lilly and Company recently announced that tirzepatide elicited superior A1C and body weight reductions from baseline in adults with type 2 diabetes with increased cardiovascular risk.
Data...
FDA recently accepted Novartis’ biologics license application for Beovu, the company’s diabetic macular edema (DME) drug.
Specifically, FDA accepted the application for six...
VisualDx and Janssen Biotech recently partnered to pilot a new application programming interface (API) and equitable artificial intelligence (AI) to enhance diagnostic accuracy.
The...
Bristol Myers Squibb recently announced interim results from a Phase 3 open-label extension trial, which showed the long-term efficacy and safety profile of Zeposia in patients with relapsing forms of...
FDA recently approved Eli Lilly and Company’s Verzenio to treat adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early breast...
FDA recently approved a new low-dose tablet dosage form of Gilead’s HIV-1 drug, Biktarvy, in pediatric patients.
The agency approved the new dosage for children weighing at least 30 pounds who...
FDA recently approved Boehringer Ingelheim’s Cyltezo as the first interchangeable biosimilar product to treat certain inflammatory diseases.
Specifically, the agency approved the drug for...
FDA recently granted Roche’s anti-amyloid beta antibody, gantenerumab, breakthrough therapy designation to treat individuals living with Alzheimer’s disease.
The agency based its...
Merck recently entered into an $11.5 billion pharma acquisition deal with biotechnology company Acceleron Pharma to strengthen its cardiovascular pipeline.
Acceleron focuses on transforming the...
GSK recently welcomed the World Health Organization’s (WHO) recommendation for the broader development of GSK’s RTS, S malaria vaccine to reduce childhood illness and deaths from malaria in...
